NEW YORK, July 14, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease, today announced that it is pleased with the recent press coverage the Company and Dr. Daniel G. Chain, Ph.D., the Company's Chairman and Chief Executive Officer, recently has received. A number of media outlets increasingly are focusing the attention of their audiences towards Alzheimer's disease, which has more than 5 million sufferers in the United States, and Dr. Chain's breakthrough efforts in finding a disease modifying treatment for this devastating, progressive, neurodegenerative and ultimately fatal disease.
On Monday, July 12, 2010, Dr. Chain was featured along with Dr. William Thies, Chief Medical & Scientific Officer of the Alzheimer's Association, on Southern California Public Radio, 89.3 KPCC by op-ed columnist and writer for the Los Angeles Times, Patt Morrison. Dr. Chain was interviewed during the Alzheimer's Association International Conference (ICAD) taking place in Honolulu (July 10-15). The conference is focused on the latest research on diagnosing, treating and preventing Alzheimer's disease.
Investors interested in hearing audio playback of the interview can find it at: http://www.scpr.org/programs/patt-morrison/2010/07/12/alzheimers-association-convenes-international-conf/
In addition, Dana Blakenhorn of ZDNet Healthcare, wrote about Dr. Chain in an article titled ,"An Alzheimer's cure could be closer than we think". That article discusses Intellect's proprietary ANTISENILIN® platform technology, which the Company has licensed to several major pharmaceutical companies that are developing drugs in Phase 1, Phase 2 and Phase 3 human clinical trials. The article can be found at http://www.zdnet.com/blog/healthcare/an-alzheimers-cure-could-be-closer-than-we-think/3793
Those interviews and other opportunities to spread the word about Intellect Neurosciences' discoveries, research and development of proprietary drug candidates follow the Company's recent successful financial restructuring, which resulted in the extinguishment of approximately $24 million of aggregate face amount plus accrued interest of debt and preferred stock through the issuance of common stock. Simultaneous with the restructuring, several of the Company's existing shareholders contributed additional funds and committed to support the Company's operations through completion of important future milestones.
About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. is a Manhattan-based biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other disorders. The Company's drug product pipeline includes OX1, which has been tested in Phase 1 clinical trials; IN-N01, a humanized monoclonal antibody designed to promote the clearance of soluble amyloid beta; and RECALL-VAX, a vaccine technology that has the potential to delay or prevent Alzheimer's disease in people who are at risk.
The Company has significant intellectual property assets, which include several patent families underlying the Company's internal programs, and a pivotal patent estate regarding passive AD immunotherapy.
The Company's ANTISENILIN® patent estate claims monoclonal antibodies that bind either end of amyloid beta but do not interact with the amyloid precursor protein from which amyloid beta is produced in the body. This high degree of specificity is an important safety feature reducing the potential for adverse affects. Examples of monoclonal antibodies exhibiting this property are Bapineuzumab and PF-04360365/RN1219 in Alzheimer's Phase 3 and Phase 2 clinical trials, respectively (http://clinicaltrials.gov/ct2/show/NCT00574132?term=bapineuzumab&rank=1; http://clinicaltrials.gov/ct2/results?term=PF-04360365).
Patents have been granted in Europe, Japan, China and elsewhere, and are pending in the United States. Intellect has granted royalty-bearing licenses to its ANTISENILIN® patent estate to several top tier global pharmaceutical companies developing monoclonal antibodies for Alzheimer's disease. For further information, see the Company's filings with the Securities and Exchange Commission, including Forms 8-K filed on:
May 1, 2009
http://www.sec.gov/Archives/edgar/data/1337905/000114420409023426/v147731_8k.htm
January 8, 2009
http://www.sec.gov/Archives/edgar/data/1337905/000114420409000980/0001144204-09-000980-index.htm
October 14, 2008
http://www.sec.gov/Archives/edgar/data/1337905/000114420408057464/0001144204-08-057464-index.htm
May 19, 2008
http://www.sec.gov/Archives/edgar/data/1337905/000114420408030722/v115138_8k.htm
For additional information, please visit http://www.intellectns.com, or contact Elliot Maza, JD, CPA, President & Chief Financial Officer, Intellect Neurosciences, Inc., 7 West 18th Street, 9th Floor, New York, NY 10011, USA. Tel: 212-448-9300 or 201-259-5706.
Safe Harbor Statement Regarding Forward-Looking Statements
The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K, (file no. 333-128226) filed on October 13, 2009, and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2010, filed on May 17, 2010.